FRAGMIN Resource Center
Eisai offers resources to assist you and your staff in the education and administration of FRAGMIN.Learn more >
FRAGMIN Self-Injection Demo Video
This Self-Injection Demo Video walks patients through the steps of injecting with a fixed-dose or graduated syringe.Learn more >
FRAGMIN Patient Education and Administration Kits
Educational materials, including an easy-to-understand reference chart, a step-by-step product brochure, and a how-to demonstration video, introduce patients to the use of FRAGMIN at home.Learn more >
Significant 44% DVT/PE relative risk reduction in medical thromboprophylaxis
Primary endpoint was incidence of proximal or distal DVT/PE or sudden death by day 21.
- There were no significant differences in the incidence of symptomatic VTE (0.6% for FRAGMIN vs 1.0% for placebo), PE (0.3% vs 0.3%), and sudden death (0.3% vs 0.2%) between the FRAGMIN and placebo arms1
Sustained prophylactic effect
- Prophylactic effect was sustained through day 901
- The incidence of symptomatic VTE was 0.93% in the FRAGMIN group and 1.33% in the placebo group (P=NS)3
PREVENT=PRospective Evaluation of dalteparin efficacy for prevention of VTE in immobilized patieNts Trial. In the FRAGMIN PREVENT trial, 3681 acutely ill patients were randomized to receive either FRAGMIN 5000 IU subcutaneously or placebo, once-daily for 14 days.